• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by I-MAB

    5/15/25 7:00:04 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    6-K 1 i-mab_6k_q1_2025.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

     

     

    Commission File Number: 001-39173

     

     

    I-MAB

    2440 Research Boulevard, Suite 400

    Rockville, MD 20850

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒                Form 40-F ☐

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    EXPLANATORY NOTE

    I-Mab (the “Registrant”) is filing this Form 6-K to furnish a press release issued on May 15, 2025, announcing financial results for the three months ended March 31, 2025, which is furnished herewith as Exhibit 99.1.

    Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684 and File No. 333-279842) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


    EXHIBIT INDEX

     

    Exhibit No.

    Description

     

     

    99.1

    Press Release – I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    I-MAB

     

     

     

    By

    :

    /s/ Joseph Skelton

     

    Name

    :

    Joseph Skelton

     

    Title

    :

    Chief Financial Officer

     

    Date: May 15, 2025


    Get the next $IMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Siebert Williams Shank initiated coverage on I-Mab with a new price target

      Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

      12/9/21 8:33:47 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on I-MAB with a new price target

      Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

      11/1/21 4:39:06 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

      HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

      9/1/21 6:14:32 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

      Virtual investor event planned for July 8th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at ESMO GI on July 2, 2025 ROCKVILLE, Md., June 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it will host a webinar to recap new givastomig data being presented at ESMO GI 2025, with a key opinion leader (KOL), on Tuesday, July 8, 2025 at 2:00pm EDT. To register, click here. The event will feature Samuel J. Klempner, MD (Associ

      6/18/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

      ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) ("I-Mab" or the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Listing Rule"). The Company's American Depositary Shares ("ADSs") will continue to be listed and traded on Nasdaq. To regain compliance with the Listing Rule, the Company's ADSs were required to maintain a minimum c

      6/12/25 6:59:59 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series

      ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the H.C. Wainwright "HCW@Home" Series, being held virtually on Tuesday, June 17, 2025. The discussion will cover a general overview of the Claudin 18.2 landscape as a validated therapeutic target for gastric cancers. The session will also offer a particular focus on givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody that is being developed in Claudin 18.2-positive gastric cancers.

      6/3/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    SEC Filings

    See more
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      6/12/25 7:05:03 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      6/2/25 7:00:27 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      5/30/25 7:36:48 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Financials

    Live finance-specific insights

    See more
    • I-Mab to Release Q3 2024 Financial Results on November 14, 2024

      ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

      10/31/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

      Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

      8/28/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Release 1H 2024 Financial Results on August 28, 2024

      Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

      8/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care